In Depth 1 Feb 2023 The future of cancer treatment: Exploiting cancer’s key vulnerabilities …across the globe to raise awareness of the disease’s devastating impact and encourage efforts to improve prevention, detection and treatment. Over the past two decades, advances in diagnosis and treatment… February 1, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 18 Nov 2025 Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates …two, given the extracellular release, the bystander effect is highly active in these therapies, meaning that both FAP-positive cells in the stroma and FAP-negative tumor cells are killed by the released payload.” … November 18, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jul 2018 Celyad’s Donor Cell CAR-T Therapy Gets Closer to the Clinic …treatment. The Belgian biotech has been cleared to test its CAR-T cell therapy, made from donor cells, in patients with unresectable colorectal cancer in combination with chemotherapy. The technology could… July 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 16 Jul 2025 Eight rare autoimmune diseases biotechs are fighting to treat …for Graves’ disease are emerging, including antigen-specific immunotherapy, B-cell depletion therapies, and targeted therapies against the TSH receptor, a protein found on thyroid cells that binds to thyroid-stimulating hormone (TSH),… July 16, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Spanish research institution to use Elicera Therapeutics’ iTANK platform …company’s technology platform for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed …starves tumors to death without damaging healthy cells. One of the key advantages is that red blood cells don’t have any genetic material, deeming them safer than other cell therapies…. November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Sunshine Biopharma acquires Nora Pharma …demonstrated the effectiveness of Adva-27a at destroying multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 20 Oct 2023 Beyond Biotech podcast 68 – rejuvenation with stem cells …cells have the ability not only to stay young but also to undergo rejuvenation when forced to age. Clock.bio’s approach is to harness this power of ‘resetting the clock’ in… October 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Syena created to deliver first-in-class TCR-NK cell therapy …generation of cell therapy, combining the safety, potency, and scalability of NK cells with the ability of TCRs to target intracellular tumor antigens. The new company’s TCR-NK cell platform is… February 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Evotec and Sanofi Hit the First Milestone for a Diabetes Cell Therapy …partnered to jointly develop a beta cell replacement therapy for the treatment of diabetes in a deal that could reach more than €300M in potential milestone payments. Today, the first… April 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients …builds on our leading-edge, combination focused development efforts that includes chemotherapy, targeted agents and immune checkpoint inhibitors. We are eager to show that Actimab-A will produce better post-eHSC transplant outcomes… December 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2024 Spinal cord injury: Are we getting closer to a treatment? …(PTPσ) to remove the natural barriers that inhibit nerve regeneration, paving the way for the body to heal itself. Let’s take a closer look at what might be the future… October 7, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email